Side-by-side · Research reference
ARA 290vsChonluten
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BAnimal-MechanisticHUMAN-REVIEWED8/38 cited
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
01Mechanism of Action
Parameter
ARA 290
Chonluten
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
Bronchial epithelial cells and respiratory mucosa tissue complexes
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Antibody development
Not reported in clinical trials
—
02Dosage Protocols
Parameter
ARA 290
Chonluten
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
Once or twice daily
Duration
28 days (Phase 2)Culver 2017
Corneal nerve improvements observed by day 28.
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
In vitro mechanistic
Route
SubcutaneousBrines 2015
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
Timing
Any time of day
No circadian dependence reported.
—
Typical protocol dose
—
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
Clinical validation
—
None (PubMed indexed)
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
Chonluten
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
04Side Effects & Safety
Parameter
ARA 290
Chonluten
Injection site reaction
Mild, transient
—
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Documented adverse events
—
No published safety data in PubMed-indexed literature
Theoretical risks
—
Peptide hypersensitivity, GI intolerance (uncharacterized)
Drug interactions
—
Unknown — no pharmacokinetic studies available
Pregnancy / lactation
—
No data — avoid
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
Chonluten
- ·Known hypersensitivity to peptide components
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
05Administration Protocol
Parameter
ARA 290
Chonluten
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
Chonluten
— no documented stacks